secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021665
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete
---------------------------------------------------------------------------

- Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.
- Net loss $95.0M vs $60.5M in Q1 2023; R&D expenses rose to $94.6M from $58.1M.
- VAX-31 adult Ph1/2 enrollment completed; topline safety/immunogenicity data expected Q3 2024.
- VAX-24 infant Ph2 enrollment completed; topline data from primary series expected by end Q1 2025.
- Plan to advance either VAX-24 or VAX-31 to adult Ph3 after VAX-31 data; if VAX-24, Ph3 start H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/0001628280-24-021665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/pcvx-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer